Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Advances in JAK Inhibitors for Severe Alopecia Areata
Description
The speaker reviews the rapid progress in treating severe alopecia areata with oral JAK inhibitors, noting that a single 2014 case report of off-label tofacitinib showing hair regrowth helped launch the field. He explains that current evidence focuses on patients with severe disease (SALT 50–100) and that topical therapies generally do not work in this population. He summarizes efficacy data for several oral agents: baricitinib, ritlecitinib, deuruxolitinib, and the emerging upadacitinib, emphasizing that higher doses often yield better responses and that outcomes improve the longer treatment continues, sometimes up to a year or more. A major theme is patience and treatment optimization: assess response after at least 6–9 months, recognize that some patients respond late, and consider switching to another JAK inhibitor if one fails. He also stresses that successful treatment usually requires long-term maintenance rather than abrupt stopping; tapering, if done, should be very gradual over long periods. Oral minoxidil is highlighted as a useful adjunct, possibly synergistic with JAK inhibitors, and bid dosing is favored. Overall, he argues that JAK inhibitors are now first-line therapy for severe alopecia areata, with treatment decisions guided by disease severity and broader clinical context rather than SALT score alone.
View moreConclusions
- Oral JAK inhibitors have clearly improved outcomes in severe alopecia areata, with several agents producing meaningful SALT score responses in clinical trials.
- Higher doses and longer treatment durations generally lead to better hair regrowth, and many patients continue improving well beyond the first few months.
- Earlier intervention, before complete scalp hair loss, appears to produce better responses than waiting until disease is fully advanced.
- No single JAK inhibitor works for every patient, but switching to another JAK inhibitor can still succeed after failure of one or more prior agents.
- Treatment should usually be continued for at least 6 to 9 months before declaring failure, because some patients respond late.
- Once hair regrowth is achieved, JAK inhibitors are typically intended as long-term maintenance therapy rather than short courses.
- If dose reduction is attempted, it should be done slowly over many months because abrupt stopping often leads to relapse.
- Oral minoxidil may be a useful adjunct to JAK inhibitor therapy and may enhance overall regrowth.
- By 2025, JAK inhibitors have become first-line therapy for severe alopecia areata, while milder disease may still be managed with older local treatments.
- The overall research suggests that severe alopecia areata is now a treatable chronic disease, but patience, persistence, and individualized switching strategies are essential.
- Craiglow BG, King BA. Oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014.
- King B, et al. N Engl J Med 2022;386(18):1687-1699.
- Senna M, et al. AAD 2024, P51840.